


Neurology
Speaker: Steven J. Smith, PhD
Alzheimer’s disease (AD) affects an estimated 24 million people worldwide. Although several medications have been FDA approved for the treatment of AD, there is still an urgent need for new therapies because like other forms of dementia, AD is complex and difficult to treat with one drug or intervention.
We know how important innovative, translatable animal models are to research that focuses on accelerating the identification of new drug targets and developing new therapies for diseases like AD. In this webinar we will introduce you to our novel AD mouse models, specifically our FAD4T mice and our Next-Generation AD models. We will also describe other exciting models available for researching various neurodegenerative diseases.
More information about blogs


Upcoming
Selecting the right humanized mouse model is one of the most consequential decisions in immuno-oncology (IO) drug development. The wrong model can mask safety liabilities, inflate efficacy estimates, and weaken the data supporting regulatory submissions. Join GemPharmatech for a data-driven webinar on how strategic humanized mouse model selection strengthens preclinical decision-making, sharpens translational relevance, and supports IND-enabling studies.
2026-07-30 00:00:00
11:00 AM ET
Xinjie Lian


On-Demand
Hypertrophic cardiomyopathy (HCM) is a prevalent and genetically heterogeneous cardiovascular disorder, with approximately 55% of familial cases linked to mutations in sarcomeric genes. To enable mechanistic and therapeutic studies, GemPharmatech has successfully developed two HCM mouse models: the Mybpc3 knockout (KO) and the Myh6 R404Q (point mutation) strains.
2026-06-25 00:00:00
11:00 AM ET
Yue Shen, Ph.D.


On-Demand
Antibody-drug conjugates (ADCs), particularly the HER2-targeting Enhertu (DS-8201), have revolutionized targeted cancer therapy. Despite their clinical success, drug resistance remains a major hurdle limiting long-term therapeutic benefits. To address this challenge, GemPharmatech has developed multiple ADC resistance models, including a HER2-positive JIMT-1 breast cancer xenograft (CDX) model with acquired resistance to Enhertu, and a primary Enhertu-resistant HER2-positive lung cancer model from our patient-derived xenograft (PDX) library. Join us to explore how these Enhertu-resistant models serve as translational tools to elucidate resistance mechanisms and evaluate novel therapeutic strategies.
2026-04-14 00:00:00
11:00 AM ET
Shiying Guo, Ph.D.

Let us know which event you're attending and we'd be happy to connect with you.
This website will store cookies on your computer. These cookies are used to collect information about how you interact with this website and enable us to remember you. We use this information to improve and customize your browsing experience, as well as to analyze and collect relevant data and metrics about visitors on this website and other platforms. For more information about the cookies we use, please refer to our privacy policy
If you decline, your information will not be tracked when visiting this website. A cookie will be used in your browser to remember your preference settings that you have not accepted.
